Biblio
Export 2567 results:
Author [ Title] Type Year Filters: First Letter Of Last Name is S [Clear All Filters]
“The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes.”, J Alzheimers Dis, vol. 94, no. 2, pp. 497-507, 2023.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-amyloid β autoantibodies in cerebral amyloid angiopathy-related inflammation: implications for amyloid-modifying therapies.”, Ann Neurol, vol. 73, no. 4, pp. 449-58, 2013.
, “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
, “Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift.”, Neuron, vol. 69, no. 2, pp. 203-13, 2011.
, “Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 64, no. 3, pp. 761-774, 2018.
, “Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function.”, J Alzheimers Dis, vol. 59, no. 3, pp. 929-939, 2017.
, “Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 86, no. 1, pp. 53-65, 2022.
, “Anticholinergic Drug Burden and Neurocognitive Performance in the Study of Latinos-Investigation of Neurocognitive Aging.”, J Alzheimers Dis, vol. 86, no. 1, pp. 53-65, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Antihypertensive Medication Class and the Risk of Dementia and Cognitive Decline in Older Adults: A Secondary Analysis of the Prospective HELIAD Cohort.”, J Alzheimers Dis, vol. 89, no. 2, pp. 709-719, 2022.
, “Antihypertensive Treatment is associated with MRI-Derived Markers of Neurodegeneration and Impaired Cognition: A Propensity-Weighted Cohort Study.”, J Alzheimers Dis, vol. 59, no. 3, pp. 1113-1122, 2017.
, “Antihypertensive Treatment is associated with MRI-Derived Markers of Neurodegeneration and Impaired Cognition: A Propensity-Weighted Cohort Study.”, J Alzheimers Dis, vol. 59, no. 3, pp. 1113-1122, 2017.
, “Antioxidants Rescue Mitochondrial Transport in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.”, J Alzheimers Dis, vol. 54, no. 2, pp. 679-90, 2016.
, “The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1485-97, 2016.
, “The Anti-Prion Antibody 15B3 Detects Toxic Amyloid-β Oligomers.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1485-97, 2016.
, “Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo.”, J Alzheimers Dis, vol. 65, no. 1, pp. 265-281, 2018.
, “Aortic Stiffness is Associated with Increased Risk of Incident Dementia in Older Adults.”, J Alzheimers Dis, vol. 66, no. 1, pp. 297-306, 2018.
, “Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis.”, J Alzheimers Dis, vol. 92, no. 1, pp. 129-139, 2023.
, “Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis.”, J Alzheimers Dis, vol. 92, no. 1, pp. 129-139, 2023.
, “Apathy as a Predictor of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Texas Alzheimer's Research and Care Consortium (TARCC) Cohort-Based Analysis.”, J Alzheimers Dis, vol. 92, no. 1, pp. 129-139, 2023.
, “APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.”, J Alzheimers Dis, vol. 69, no. 3, pp. 783-793, 2019.
, “APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points.”, J Alzheimers Dis, vol. 69, no. 3, pp. 783-793, 2019.
, “APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.”, J Alzheimers Dis, vol. 79, no. 2, pp. 511-530, 2021.
,